OSUR — OraSure Technologies Inc

OraSure Technologies Inc (OSUR) is a medical instruments & supplies company listed on NASDAQ. It is led by Carrie Eglinton Manner, based in 220 East First Street, Bethlehem, PA, United States, 18015, with about 501 employees. OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h

Latest reported OSUR revenue for 2025-09-30 was $27.1M. Net income was -$13.7M. Revenue was down 13.3% from 2025-06-30 to 2025-09-30. OSUR currently screens at market cap $225.1M.

Use this OSUR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OSUR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OSUR SEC filings page. Lician reads the product cache first so this HTML stays unique to OraSure Technologies Inc even when a live quote feed is slow.